Skip to main content

Antibody-dependent cellular cytotoxicity (ADCC) assays for functional characterization of mAb

 Antibody-dependent cellular cytotoxicity (ADCC) assays assess the ability of an antibody like nivolumab to recruit immune effector cells, such as natural killer (NK) cells, to target and kill cancer cells. However, nivolumab, an IgG4 monoclonal antibody (mAb), is generally designed to avoid ADCC due to its checkpoint inhibitor function, which is primarily intended to restore T-cell activity rather than direct cytotoxicity. Nevertheless, ADCC assays are still conducted in early drug development to confirm that nivolumab has minimal or no ADCC activity, especially since unintended cytotoxicity could lead to adverse effects.

Principle of ADCC Assay

ADCC occurs when an antibody binds to a target cell, such as a cancer cell, and its Fc region is recognized by Fc receptors (FcγR) on the surface of effector cells like NK cells. When the antibody-coated target cell is brought into proximity with the effector cell, the effector cell becomes activated and releases cytotoxic granules, leading to target cell lysis.

For nivolumab, an ADCC assay would confirm the absence of significant ADCC activity due to its IgG4 backbone, which interacts minimally with FcγR receptors and therefore has reduced cytotoxic potential.

Step-by-Step Procedure for ADCC Assay

  1. Preparation of Target Cells (Cancer Cells)

    • Culture a suitable target cell line that expresses the PD-1 ligand (PD-L1 or PD-L2). Use cell lines relevant to the nivolumab target, such as PD-L1-expressing tumor cells.
    • Label target cells with a fluorescent dye like calcein AM, or with a radioactive marker such as chromium-51 (^51Cr), depending on the detection method. Labeling helps quantify cell lysis by measuring released fluorescence or radioactivity after cell death.

  2. Preparation of Effector Cells (NK Cells)

    • Isolate peripheral blood mononuclear cells (PBMCs) from healthy donors, or use NK-92 cells, which are engineered NK cells that express Fc receptors and are effective in ADCC assays.
    • For optimal results, ensure an effector-to-target (E
      ) cell ratio (commonly 25:1 or 50:1) that provides sufficient sensitivity in detecting any ADCC activity.

  3. Addition of Nivolumab

    • Add nivolumab at various concentrations to the target cells. Include a positive control antibody (such as a therapeutic IgG1 antibody known to induce ADCC) and a negative control (such as an IgG4 isotype control) to validate the assay.
    • Incubate the antibody-target cell mixture briefly to allow nivolumab to bind to the target cells.

  4. Co-Culture of Effector and Target Cells

    • Combine the effector cells with the target cells at the specified E
      ratio.
    • Incubate the co-culture for a specific period, typically 4 hours, to allow interaction and possible cell lysis.

  5. Detection of Target Cell Lysis

    • For fluorescent assays: Measure fluorescence released into the supernatant from lysed cells using a fluorescence plate reader.

    • For radioactive assays: Measure radioactivity in the supernatant, which correlates with the number of lysed cells.

    • Calculate the percentage of specific lysis using the formula:

      Specific Lysis (%)=(Experimental Release - Spontaneous Release)(Maximum Release - Spontaneous Release)×100\text{Specific Lysis (\%)} = \frac{\text{(Experimental Release - Spontaneous Release)}}{\text{(Maximum Release - Spontaneous Release)}} \times 100

  6. Analysis and Interpretation

    • Determine the ADCC activity of nivolumab by comparing it to the positive and negative controls.
    • For nivolumab, minimal to no lysis should be observed, indicating that it does not induce significant ADCC activity due to its IgG4 Fc region. The positive control should demonstrate strong lysis, while the IgG4 isotype control should show minimal ADCC activity.

Key Considerations

  • IgG4 Backbone of Nivolumab: As an IgG4 antibody, nivolumab is engineered to avoid binding strongly to Fcγ receptors, which is reflected in a low ADCC response in this assay.
  • Positive and Negative Controls: Including an IgG1 antibody as a positive control is crucial to verify that the assay system can detect ADCC activity effectively.
  • Effector-to-Target Ratio: The E
    ratio can affect the sensitivity of the assay; higher ratios may yield better sensitivity but should be consistent across replicates.

Summary

This ADCC assay confirms that nivolumab lacks significant ADCC activity, aligning with its primary mechanism of blocking PD-1 to activate T-cells rather than directly mediating cell killing.

Popular posts from this blog

Human Genome Editing: FDA Draft Guidance Summary

Consideration for Developing Gene Editing Product  1. Genome Editing Methods: Genome editing can be achieved through nuclease-dependent or nuclease-independent methods. Nuclease-dependent methods involve introducing site-specific breaks in DNA using technologies like zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), modified-homing endonucleases, and CRISPR-associated (Cas) nucleases. These breaks can lead to modification of the DNA sequence at the cleavage site. Nuclease-independent methods can change DNA sequences without cleaving the DNA and include techniques like base editing and synthetic triplex-forming peptide nucleic acids. The choice of GE technology should consider factors such as the mechanism of action, the ability to target specific DNA sequences, and the potential to optimize components for efficiency, specificity, or stability. 2. Type and Degree of Genomic Modification: Different GE approaches rely on DNA repair pathways such a...
Read more

Stem-Loop PCR for siRNA

 Stem-loop PCR is a method often used for detecting and quantifying small RNAs, such as siRNA or miRNA, which are typically difficult to amplify directly due to their short lengths. The method involves the design of a stem-loop reverse transcription (RT) primer, which enhances specificity and stability of the short RNA during the RT-PCR process, allowing for sensitive detection and quantification of the siRNA. Here’s a detailed guide to how stem-loop PCR can be applied to siRNA detection: Key Steps in Stem-Loop PCR for siRNA Designing the Stem-Loop RT Primer : Structure : The stem-loop RT primer consists of a loop region flanked by complementary sequences on either side (the "stem"), which will fold back on itself to form a hairpin structure. Specific Binding Region : A short sequence complementary to the 3’ end of the siRNA is added at the end of the stem-loop primer to ensure specific binding to the siRNA target. Stabilization : The loop structure helps prevent primer-dimer...
Read more

Ago2 Immunoprecipitation for RISC-siRNA Quantitation

 Ago2 (Argonaute 2) immunoprecipitation (IP) is a technique used to isolate RNA-induced silencing complexes (RISC) from cell lysates. This method allows for the specific enrichment of active RISC complexes bound to small interfering RNA (siRNA) or microRNA (miRNA) within cells. By isolating these complexes, researchers can then quantify the siRNA associated with Ago2, which is an essential step in determining the efficacy of RISC loading and siRNA activity. Here’s a detailed overview of how Ago2 immunoprecipitation is performed for RISC-siRNA quantitation: Steps in Ago2 Immunoprecipitation for RISC-siRNA Quantitation Cell Lysis and Preparation of Lysate : Sample Preparation : Collect cells that have been treated with siRNA, then wash them with cold phosphate-buffered saline (PBS) to remove extracellular contaminants. Lysis : Lyse the cells in a gentle, RNA-preserving lysis buffer that typically includes detergents (e.g., NP-40 or Triton X-100), protease inhibitors, and RNase inhibi...
Read more

Guideline on development and manufacture of lentiviral vectors (CHMP/BWP/2458/03)

The guideline with the reference number "CHMP/BWP/2458/03" pertains to the "Guideline on Development and Manufacture of Lentiviral Vectors." This guideline was developed by the Committee for Medicinal Products for Human Use (CHMP) and the Biotechnology Working Party (BWP) of the European Medicines Agency (EMA). It provides recommendations and regulatory guidance for the development and manufacture of lentiviral vectors, which are widely used in gene therapy and cell therapy applications. Here's an overview of the key points covered in this guideline: 1. Introduction: The guideline begins with an introduction highlighting the increasing importance of lentiviral vectors in advanced therapies and the need for guidance on their development and manufacture. 2. Scope: It defines the scope of the guideline, which covers the development and manufacture of lentiviral vectors intended for use in gene therapy and cell therapy products for human use. 3. Quality and Characte...
Read more

Stem loop RT-PCR for Detection of siRNA in Animal Tissues

Step Loop RT-PCR for Detection of Small Interfering RNA (siRNA) The recent publications described a novel used the novel method for the detection of siRNAs using a TaqMan®-based approach. This approach utilizes similar strategy that has been used for microRNA detection. The approach is illustrated in below.  In brief, the RT step occurs in the presence of a stem-loop RT primer that is complementary to the last 6–10 bases of the 3′ end of the antisense strand of the target siRNA. The stem-loop primer contains an additional universal sequence at the 5′ end that facilitates a TaqMan-based detection strategy in the subsequent qPCR step. As in the case of microRNA, the forward primer for qPCR is sequence-specific for the target siRNA. For sequence compositions that yield a low predicted melting temperature (Tm), the forward primer is designed as a tailed primer to help increase Tm. Stem Loop PCR for SiRNA Detection Step 1: Preparation of liver and plasma samples for the quanti...
Read more